相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Elio Adib et al.
CLINICAL CANCER RESEARCH (2021)
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu et al.
LANCET ONCOLOGY (2021)
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of muscle-invasive and advanced bladder cancer in 2020
Vaibhav G. Patel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Defining platinum-ineligible patients with metastatic urothelial cancer (mUC).
Shilpa Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
Joaquim Bellmunt et al.
BRITISH JOURNAL OF CANCER (2018)
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
Sujata Narayanan et al.
CLINICAL GENITOURINARY CANCER (2016)
The CAMSAP3-ACF7 Complex Couples Noncentrosomal Microtubules with Actin Filaments to Coordinate Their Dynamics
Wenxiu Ning et al.
DEVELOPMENTAL CELL (2016)
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Jaegil Kim et al.
NATURE GENETICS (2016)
Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
Arlene O. Siefker-Radtke et al.
UROLOGY (2016)
The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
Zhi Liu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Guenter Niegisch et al.
ONCOLOGY (2015)
SAAS-CNV: A Joint Segmentation Approach on Aggregated and Allele Specific Signals for the Identification of Somatic Copy Number Alterations with Next-Generation Sequencing Data
Zhongyang Zhang et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A. Hurvitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Furry promotes acetylation of microtubules in the mitotic spindle by inhibition of SIRT2 tubulin deacetylase
Tomoaki Nagai et al.
JOURNAL OF CELL SCIENCE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
Satish K. Tickoo et al.
BJU INTERNATIONAL (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
M. Campone et al.
BRITISH JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Inactivation of p53 and Pten promotes invasive bladder cancer
Anna M. Puzio-Kuter et al.
GENES & DEVELOPMENT (2009)
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Unfit for Cisplatin-Based Chemotherapy: Phase II-Results of EORTC Study 30986
Maria De Santis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
Atreya Dash et al.
CANCER (2006)
Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel
L. S. Faried et al.
EUROPEAN JOURNAL OF CANCER (2006)
Interaction between p230 and MACF1 is associated with transport of a glycosyl phosphatidyl inositol-anchored protein from the Golgi to the cell periphery
T Kakinuma et al.
EXPERIMENTAL CELL RESEARCH (2004)
分享论文
